The Assisted Reproductive Technology Market was valued at USD 23.41 billion in 2024 and is expected to grow at a strong CAGR of 9.56% for the forecast period (2025-2033F)

Rising Infertility Rates: According to the World Health Organization 2024, around 17.5% of the adult population, i.e., roughly 1 in 6 worldwide, experience infertility, which shows the dire need for increased access to affordable, high-quality fertility care for the needy.

Technological Advancements: Technological developments such as Pre-Implantation Genetic Testing (PGT), Endometrial Receptivity Analysis Testing (ERA), Magnetic Activated Cell Sorting (MACS), and time-lapse imaging of embryos are expediting the Assisted Reproductive Technology Market.

Social and Cultural Acceptance: The decrease in the stigma associated with infertility and shifting family dynamics (such as same-sex couples and solo parenting) have catalyzed the increased use of ART on a global level.

Need for Ethical and Regulatory Control: There is a need for stringent ethical and regulatory control, ensuring the safety and quality of the Assisted Reproductive Technology market. It may pose risks to the health of the mother as well as the child born through Assisted Reproductive Technology procedures.

Medical Tourism: Some countries, such as the United States and India, are becoming ART hotspots because of their excellent facilities and cheaper treatment prices, enticing patients from abroad. India ranks 2nd after the United States in providing Assisted Reproductive Technology treatment.

The technological developments in assisted reproductive technology, demographic shifts toward acceptance of ART, and increased awareness of ART are all contributing factors to the rising prevalence of infertility across the population. Further inability of parents to conceive their child, increased rate of diseases such as greater body mass index, chronic hypertension, diabetes, and thyroid problems, are projected to expedite the exponential expansion worldwide. Increased infertility cases, better ART success rates, and higher disposable income in developing nations are some of the factors that are anticipated to propel industry expansion throughout the forecast period. The rising rates of infertility as a result of shifting lifestyles, increased public stress, and growing government programs to promote fertility services are driving the market growth. Sexually transmitted infections (STIs), rising cigarette smoking rates, obesity, endometriosis, PCOS, POC, and other conditions are further factors contributing to this market's significant rise. Additionally, the development of sophisticated assisted reproductive technologies, including frozen embryo transfer (FET), GIFT, and intracytoplasmic sperm injection (ICSI), backed by promising clinical outcomes, is driving the expansion of the Assisted Reproductive Technology market.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/assisted-reproductive-technology-market?popup=report-enquiry

According to the report, the impact of Assisted Reproductive Technology has been identified to be high for the Asia-Pacific area. Some of how this impact has been felt include:

Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2025-2033). The Asia-Pacific market for Assisted Reproductive Technology is growing rapidly because of the growing ART research and technological developments, owing to rising infertility rates, greater awareness of fertility treatments, and improved healthcare infrastructure. Asia-Pacific is expected to develop at the fastest rate in the Assisted Reproductive Technology (ART) market during the projected years, driven by delayed childbirth, changes in lifestyle, and stress-related infertility. For instance, according to the Japan Society of Obstetrics and Gynaecology, in 2021, the number of children born through in vitro fertilization as part of infertility treatment increased by 9,416 from the previous year to a record high of 69,797 in Japan. Further, the market is also inflating due to government regulations supporting infertility treatment, an increase in the number of fertility clinics, and advancements in reproductive technologies. The region's market is expanding due to the affordability of ART operations in comparison to Western countries and rising medical tourism. As per the World Bank 2024, 74 women die per 100,000 live births due to pregnancy-related causes in East Asia & Pacific. According to Economist Impact 2024, the fertility rates of many countries in the Asia Pacific region (APAC) have been drastically declining over the past 70 years. This has had an impact not only on the population size of these countries but also on the structure of the population. South Korea has the lowest total fertility rate (TFR) in the world at 0.8, well below the replacement rate of 2.1, and Singapore and Japan are not much higher, at 1.1 and 1.3, respectively.  

Ethical and Strict Regulations of some countries

The American medical regulation system was established to protect the public from inappropriate, dishonest, and incompetent people by restricting the practice of medicine to qualified professionals. Assisted Reproductive Technology (ART) is regulated by bodies such as the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the Centers for Medicare and Medicaid Services (CMS) in the United States. Further, the safety and efficacy of ART practices are ensured at the state level by the Society for Assisted Reproductive Technology (SART), which outlines the reasons for wrongdoing, such as dishonesty, fraud, carelessness, and abusing the doctor-patient bond. On the other hand, nations like the United Kingdom and Australia provide more extensive public funding and open regulatory frameworks, amplifying ART patients' access and results. Similarly, Italy has stringent regulations, which include restrictions on the production and transfer of embryos. On the other hand, nations like the United Kingdom and Australia provide more extensive public funding and open regulatory frameworks, amplifying ART patients' access and results.

According to preliminary data from the Society for Assisted Reproductive Technology (SART), in 2022, the number of babies born from IVF increased from 89,208 in 2021 to 91,771 in 2022. This increase means that 2.5% of all births in the US result from successful ART cycles. The increased number of cycles performed reflects a steady rise in demand for fertility services, even in the face of hostile legislation and threats of political interference.

Click here to view the Report Description & TOC: https://univdatos.com/reports/assisted-reproductive-technology-market

Infertility in the United States

Infertility-related involuntary childlessness can have a significant negative influence on a person's life, leading to psychological, social, physical, and financial difficulties. Furthermore, the social structure and stability of extended families, as well as their communities, are adversely affected by the hurdles that arise during the family-building process, with consequences that extend well beyond the individual.

According to the National Survey of Family Growth 2021:

Approximately 7.4 million women in the United States, or approximately 12.1% of women of reproductive age experience difficulty having children because of impaired fecundity.

Approximately 9.4% of men are sub fertile or nonsurgically sterile.

For many of these people, safe and effective methods of addressing infertility are needed but are unaffordable or otherwise inaccessible.

According to the Centers for Disease Control and Prevention, 2022, ART Use by Age Group, United States, 2022

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2025−2033.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis by Product, by Technology, by End-User, by Region/Country

Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Contact Us:

UnivDatos

Email: contact@univdatos.com 

Contact no: +1 978 7330253

Website: www.univdatos.com

Linked In: https://www.linkedin.com/company/univ-datos/